Ligand to Participate in Two Upcoming Investor Conferences
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Tech stocks weigh on Wall Street as Iran stalemate lifts oil, yields
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Trump threatens to bomb Oman over Iran stance
- U.S. EV market shows signs of bottoming out: Bernstein
Ligand Pharma (LGND) PT Raised to $182 at H.C. Wainwright
March 7, 2018 8:25 AM ESTH.C. Wainwright raised its price target on Ligand Pharma (NASDAQ: LGND) to $182.00 (from $170.00) while maintaining a Buy rating.
Analsyt Joseph Pantginis commented, "Yesterday, Ligand delivered on one of our more important projections, namely a global partnership for LGD-6972. The transaction was with with... More
